The lethality of common (surface) epithelial ovarian cancer is contingent on its metastatic capacity. Dissemination of the neoplasia throughout the abdominal cavity has been associated with secretion of proteolytic enzymes from vesicles shed by ovarian cancer cells. We report that the lipophilic steroid hormone progesterone decreases the fluid dynamics of plasma membranes of human SKOV-3 adenocarcinoma cells. The decrease in membrane fluidity was related to an inhibition in vitro of exocytotic vesicle release, cellular invasiveness into Matrigel, and colony formation in three-dimensional collagen matrix. Tumorigenesis was suppressed by progesterone in immunocompromised nude mice inoculated intraperitoneally with SKOV-3 cells. Progestins could therefore be of benefit in the prevention and(or) treatment of early-stage ovarian carcinomatosis.
BrannDW, HendryLB, MaheshVB. Emerging diversities in the mechanism of action of steroid hormones. J Steroid Biochem Mol Biol52: 113–133, 1995.
5.
GoldenGA, MasonPE, RubinRT, MasonRP. Biophysical membrane interactions of steroid hormones: A potential complementary mechanism of steroid action. Clin Neuropharmacol21: 181–189, 1998.
6.
StackMS, EllerbroekSM, FishmanDA. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma. Int J Oncol12: 569–576, 1998.
7.
DoloV, D'ascenzoS, VioliniS, PompucciL, FestucciaC, GinestraA, VittorelliML, CanevariS, PavanA. Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro. Clin Exp Metast17: 131–140, 1999.
8.
Dan⊘K, AndreasenPA, Gr⊘ndahl-HansenJ, KristensenP, NielsenLS, SkriverL. Plasminogen activators, tissue degradation, and cancer [review]. Adv Cancer Res44: 139–266, 1985.
9.
McDonnelAC, MurdochWJ. High-dose progesterone inhibition of urokinase secretion and invasive activity by SKOV-3 ovarian carcinoma cells: evidence for a receptor-independent nongenomic effect on the plasma membrane. J Steroid Biochem Mol Biol78: 185–191, 2001.
10.
RischHA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst90: 1774–1786, 1998.
11.
HuaW, ChristiansonT, RougeotC, RochefortH, ClintonGM. SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens. J Steroid Biochem Mol Biol55: 279–289, 1995.
12.
AbrahamGE, OdellWS, SwerdloffRS, HopperR. Simultaneous radioimmunoassays of plasma FSH. LH. progesterone. 17-OH progesterone and estradiol during the menstrual cycle. J Clin Endocrinol Metab45: 312–318, 1972.
13.
McNattyKP, HunterWM, McNeillyAS, SawersRS. Changes in the concentration of pituitary and steroid hormones in the follicular fluid of human graafian follicles throughout the menstrual cycle. J Endocrinol64: 555–571, 1975.
14.
KuhryJ, DuportailG, BronnerC, LaustriatG. Plasma membrane fluidity measurements on whole living cells by fluorescence anisotropy of trimethylammoniumdiphenylhexatriene. Biochim Biophys Acta845: 60–67, 1985.
15.
HauglandRP. Handbook of Fluorescent Probes and Research Chemicals. Eugene: Molecular Probes Inc., 1996.
16.
ShinitzkyM, BarenholzY. Fluidity parameters of lipid regions determined by fluorescence polarization. Biochim Biophys Acta515: 367–394, 1978.
17.
HorváthI, GlatzA, VarvasoszkiV, TörökZ, PáliT, BaloghG, KovácsE, NádasdiL, BenköS, JoóF, VíghL. Membrane physical state controls the signaling mechanism of the heat shock response in Synechocystis PCC 6803: Identification of hspl7 as a fluidity gene. Proc Natl Acad Sci USA95: 3513–3518, 1998.
18.
DoloV, GinestraA, GhersiG, NagaseH, VittorelliML. Human breast carcinoma cells cultured in the presence of serum shed membrane vesicles rich in gelatinolytic activities. J Submicr Cytol Pathol26: 173–180, 1994.
19.
SherbetGV. Membrane fluidity and cancer metastasis. Exp Cell Biol57: 198–205, 1989.
20.
WhitingKP, RestallCJ, BrainPF. Steroid hormone-induced effects on membrane fluidity and their potential roles in non-genomic mechanisms. Life Sci67: 743–757, 2000.
21.
Van BommelT, MarsenT, BojarH. Effects of high-dose medroxyprogesterone acetate and various other steroid hormones on plasma membrane lipid mobility in CAMA-1 mammary cancer cells. Anticancer Res7: 1217–1223, 1987.
22.
UedaM, FujiiH, YoshizawaK, KumagaiK, UekiK, TeraiY, YangaiharaT, UekiM. Effects of sex steroids and growth factors on invasive activity and 5′-deoxy-5-fluoruridine sensitivity in ovarian adenocarcinoma OMC-3 cells. Jpn J Cancer Res89: 1334–1342, 1998.
23.
BerchuckA, CarneyM. Human ovarian cancer of the surface epithelium. Biochem Pharmacol54: 541–544, 1997.
24.
AuerspergN, EdelsonMI, MokSC, JohnsonSW, HamiltonTC. The biology of ovarian cancer. Semin Oncol25: 281–304, 1998.
25.
BakerVV. The pathogenesis of epithelial ovarian cancer. J Clin Ligand Assay21: 438–441, 1998.
26.
MurdochWJ, McDonnelAC. Roles of the ovarian surface epithelium in ovulation and carcinogenesis. Reproduction123: 743–750, 2002.
27.
ShukovskiL, TsafririA. The involvement of nitric oxide in the ovulatory process in the rat. Endocrinology135: 2287–2290, 1994.
28.
MurdochWJ. Plasmin-tumour necrosis factor interaction in the ovulatory process. J Reprod Fertil Suppl54: 353–358, 1999.
29.
NessRB, CottreauC. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst91: 1459–1467, 1999.
30.
KodamanPH, BehrmanHR. Endocrine-related and protein kinase C-dependent generation of superoxide by rat preovulatory follicles. Endocrinology142: 687–693, 2001.
31.
MurdochWJ, TownsendRS, McDonnelAC. Ovulation-induced DNA damage in ovarian surface epithelial cells of ewes: Prospective regulatory mechanisms of repair/survival and apoptosis. Biol Reprod65: 1417–1424, 2001.
32.
MurdochWJ. Programmed cell death in preovulatory ovine follicles. Biol Reprod53: 8–12, 1995.
33.
MurdochWJ. Ovarian surface epithelium during ovulatory and anovulatory ovine estrous cycles. Anat Ree240: 322–326, 1994.
SchmalfeldtB, PrechtelD, HartingK, SpatheK, RutkeS, KonikE, FridmanR, BergerU, SchmittM, KuhnW, LengyelE. Increased expression of matrix metalloproteinase (MMP)-2. MMP-9. and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res7: 2396–2404, 2001.
41.
ChambersSK, GertzRE, IvinsCM, KacinskiBM. The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer75: 1627–1633, 1995.
42.
GinestraA, MiceliD, DoloV, RomanoFM, VittorelliML. Membrane vesicles in ovarian cancer fluids: A new potential marker. Anticancer Res19: 3439–3445, 1999.
43.
BehrendtN, R⊘nneE, Dan⊘K. The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface. Biol Chem376: 269–279, 1995.
44.
KobayashiH, MoniwaN, SugimuraM, ShinoharaH, OhiH, TeraoT. Increased cell-surface urokinase in advanced ovarian cancer. Jpn J Cancer Res84: 633–640, 1993.
45.
PedersenN, SchmittM, R⊘nneE, NicolettiMI, H⊘yer-HansenG, ConeseM, GiavazziR, Dan⊘K, KuhnW, JänickeF, BlasiF. A ligand-free, soluble urokinase receptor is present in ascitic fluid from patients with ovarian cancer. J Clin Invest92: 2160–2167, 1993.
46.
WahlbergG, H⊘yer-HansenG, CasslenB. Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer. Cancer Res58: 3294–3298, 1998.
47.
KobayashiH, OhiH, SugimuraM, ShionharaH, FujiiT, TeraoT. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res52: 3610–3614, 1992.
48.
WilhelmO, SchmittM, HohlS, SenekowitschR, GraeffH. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metast13: 296–302, 1995.
